HaythemYAliMD

Oncology • Detroit, MI

Breast Cancer, Head & Neck Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Ali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ali's full profile

Already have an account?

Office
Henry Ford Health System
2799 Wgrand BLVD
Detroit, MI 48202
Phone+1 313-916-7648

Education & Training

Ascension Providence/MSUCHMFellowship, Hematology and Medical Oncology, 1996 - 1998
Ascension Providence/MSUCHMResidency, Internal Medicine, 1993 - 1996
University of Baghdad College of MedicineClass of 1988

Certifications & Licensure

MI State Medical License 1995 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer Start of enrollment: 2007 Feb 01
Terminated
Phase 2, Phase 3
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Start of enrollment: 2010 Dec 01
Completed
Phase 3
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol Start of enrollment: 2014 Mar 01
Unknown status
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Start of enrollment: 2015 Aug 01
Completed
Phase 1, Phase 2
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC Start of enrollment: 2017 Dec 21
Terminated
Phase 3
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model.
Azizur Rahman, Branislava Janic, Tasnim Rahman, Harshit Singh, Haythem Ali
Cancers. 2023-10-11
2 citations
Short-term changes in ultrasound tomography measures of breast density and treatment-associated endocrine symptoms after tamoxifen therapy.
Cody Ramin, Ruth M Pfeiffer, Sharon Fan, Maeve Mullooly, Roni T Falk
NPJ Breast Cancer. 2023-03-15
8 citations
A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma.
Shyam Nyati, Hans Stricker, Kenneth N Barton, Pin Li, Mohamed Elshaikh
Plos One. 2023-01-01

Journal Articles

Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...
H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology

Lectures

A differential response to cetuximab in patients with recurrent unresectable or metastatic head and neck cancer following immunotherapy (IO) exposure: An institutional...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

OncLive® to Host State of the Science Summit™ on Breast CancerMay 8th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
European society of medical oncology
Member